Soluble epoxide hydrolase inhibitors and cardiovascular diseases

Current Vascular Pharmacology

Volumn 11, Issue 1, 2013, Pages 105-111

  Wang, Zhen He ^a   Davis, Benjamin B ^b   Jiang, De Qian ^a   Zhao, Ting Ting ^a   Xu, Dan Yan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiovascular diseases; Epoxyeicosatrienoic acids; Soluble epoxide hydrolase

Indexed keywords

CYTOCHROME P450; DEOXYCORTICOSTERONE ACETATE; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE INHIBITOR; EPOXYICOSATRIENOIC ACID; HYDROLASE INHIBITOR; ION CHANNEL; PROSTAGLANDIN SYNTHASE; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; REPERFUSION INJURY;

EID: 84873202544     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016113804547593     Document Type: Article

References (43)

1. Behm DJ, Ogbonna A, Wu C, et al. Epoxyeicosatrienoic acids function as selective, endogenous antagonists of native thromboxane receptors: identification of a novel mechanism of vasodilation. J Pharmacol Exp Ther 2009; 328: 231-9.
2. Yang C, Kwan YW, Au AL, et al. 14,15-Epoxyeicosatrienoic acid induces vasorelaxation through the prostaglandin EP(2) receptors in rat mesenteric artery. Prostaglandins Other Lipid Mediat 2010; 93: 44-51.
3. Sun J, Sui X, Bradbury JA, et al. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res 2002; 90: 1020-7.
4. Spector AA, Fang X, Snyder GD, et al. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 2004; 43: 55-90.
5. Gill SS, Hammock BD, Casida JE. Mammalian metabolism and environmental degradation of the juvenoid 1-(4-ethylphenoxy)3,7-dimethyl-6, 7-epoxy-trans2-octene and related compounds. J Agric Food Chem 1974; 22: 386-95.
6. Newman JW, Morisseau C, Harris TR, et al. The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc Natl Acad Sci USA 2003; 100: 1558-63.
7. Fornage M, Boerwinkle E, Doris PA, et al. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circulation 2004; 109: 335-9.
8. Burdon KP, Lehtinen AB, Langefeld CD, et al. Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular diseases in the Diabetes Heart Study. Diab Vasc Dis Res 2008; 5: 128-34.
9. Lee CR, North KE, Bray MS, et al. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum Mol Genet 2006; 15: 1640-9.
10. Motoki A, Merkel MJ, Packwood WH, et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am J Physiol Heart Circ Physiol 2008; 295: H2128-34.
11. Monti J, Fischer J, Paskas S, et al. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet 2008; 40: 529-37.
12. Manhiani M, Quigley JE, Knight SF, et al. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol 2009; 297: F740-748.
13. Inceoglu B, Jinks SL, Schmelzer KR, et al. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci 2006; 79: 2311-9.
14. Inceoglu B, Jinks SL, Ulu A, et al. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc Natl Acad Sci USA 2008; 105: 18901-6.
15. Schmelzer KR, Kubala L, Newman JW, et al. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA 2005; 102: 9772-7.
16. Smith KR, Pinkerton KE, Watanabe T, et al. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci USA 2005; 102: 2186-91.
17. Schmelzer KR, Inceoglu B, Kubala L, et al. Enhancement of antinociception by coadministration of non-steroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 2006; 103: 13646-51.
18. Liu JY, Yang J, Inceoglu B, et al. Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol 2010; 79: 880-7.
19. Xu D, Li N, He Y, et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 2006; 103: 18733-8.
20. Aboutabl ME, Zordoky BN, El-Kadi AO. 3-methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats. Br J Pharmacol 2009; 158: 1808-19.
21. Ai D, Pang W, Li N, et al. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci USA 2009; 106: 564-9.
22. Elmarakby AA. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease. J Physiol Regul Integr Comp Physiol 2011; Nov 23 [Epub ahead of print].
23. Batchu SN, Law E, Brocks DR, et al. Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. J Mol Cell Cardiol 2009; 46: 67-74.
24. Chaudhary KR, Abukhashim M, Hwang SH, et al. Inhibition of soluble epoxide hydrolase by trans-4-[4-(3-adamantan-1-ylureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury. J Cardiovasc Pharmacol 2010; 55: 67-73.
25. Katragadda D, Batchu SN, Cho WJ, et al. Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells. J Mol Cell Cardiol 2009; 46: 867-75.
26. Enayetallah AE, Luria A, Luo B, et al. Opposite Regulation of Cholesterol Levels by the Phosphatase and Hydrolase Domains of Soluble Epoxide Hydrolase. J Biol Chem 2008; 283: 36592-8.
27. Pinot F, Grant DF, Spearow JL, et al. Differential regulation of soluble epoxide hydrolase by clofibrate and sexual hormones in the liver and kidneys of mice. Biochem Pharmacol 1995; 50: 501-18.
28. Ulu A, Davis BB, Tsai HJ, et al. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein Eknockout mouse model. J Cardiovasc Pharmacol 2008; 52: 314-23.
29. Zhang LN, Vincelette J, Cheng Y, et al. Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia. Arterioscler Thromb Vasc Biol 2009; 29: 1265-70.
30. Revermann M, Schloss M, Barbosa-Sicard E, et al. Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice. Arterioscler Thromb Vasc Biol 2010; 30: 909-14.
31. Simpkins AN, Rudic RD, Roy S, et al. Soluble epoxide hydrolase inhibition modulates vascular remodeling. Am J Physiol Heart Circ Physiol 2010; 298: H795-806.
32. Li J, Carroll MA, Chander PN, et al. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. Front Biosci; 2008; 13: 3480-7.
33. Loch D, Hoey A, Morisseau C, et al. Prevention of Hypertension in DOCA-Salt Rats by an Inhibitor of Soluble Epoxide Hydrolase. Cell Biochem Biophys 2007; 47: 87-98.
34. Huang H, Morisseau C, Wang J, et al. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am J Physiol Renal Physiol 2007; 293: 342-9.
35. Olearczyk JJ, Field MB, Kim IH, et al. Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels. J Pharmacol Exp Ther 2006; 318: 1307-14.
36. Jiang JG, Chen RJ, Xiao B, et al. Regulation of endothelial nitricoxide synthase activity through phosphorylation in response to epoxyeicosatrienoic acids. Prostaglandins Other Lipid Mediat 2007; 82: 162-74.
37. Chawengsub Y, Aggarwal NT, Nithipatikom K, et al. Identification of 15-hydroxy-11,12-epoxyeicosatrienoic acid as a vasoactive 15-lipoxygenase metabolite in rabbit aorta. Am J Physiol Heart Circ Physiol 2008; 294: H1348-1356.
38. Gross GJ, Gauthier KM, Moore J, et al. Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol 2008; 294: H2838-2844.
39. Merkel MJ, Liu L, Cao Z, et al. Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling. Am J Physiol Heart Circ Physiol 2010; 298: 679-87.
40. Chaudhary KR, Cho WJ, Daniel EE, et al. 06 Epoxyeicosatrienoic acid mediated cardioprotection involves mitochondrial caveolin-1 and PKCe. Heart 2011; 97: e8.
41. Hutchens MP, Nakano T, Dunlap J, et al. Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation. Resuscitation 2008; 76: 89-94.
42. Lee J, Dahl M, Grande P, et al. Genetically reduced soluble epoxide hydrolase activity and risk of stroke and other cardiovascular disease. Stroke 2010; 41: 27-33.
43. Kullmann S, Binner P, Rackebrandt K, et al. Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention. BMC Cardiovasc Disord 2009; 9: 48.